Rebound case of COVID-19 after treatment with Paxlovid therapy was completed; This spontaneous case was reported by a patient and describes the occurrence of COVID-19 (Rebound case of COVID-19 after treatment with Paxlovid therapy was completed) in a 60-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 003J21-2A and 059E21A) for COVID-19 vaccination.     The patient's additional medical history included +AMA The patient had sulfa antibiotic allergy.  Concurrent medical conditions included Hypogammaglobulinemia, GERD, Osteopenia, Degenerative disc disease, Iron deficiency anemia, Osteoarthritis, Mixed connective tissue disease, Fibromyalgia, Allergy to antibiotic (Allergy to Levaquin), Drug allergy (Allergy Sulindac,), Lactose intolerance, Environmental allergy and Allergy to antibiotic (Allergy to Ceftriaxone). Concomitant products included CEFIXIME (SUPRAX [CEFIXIME]) from 10-May-2022 to 23-May-2022, BUPRENORPHINE (BUTRANS) from 18-Apr-2022 to an unknown date, METAXALONE (SKELAXIN [METAXALONE]), TOPIRAMATE, MACROGOL 3350 (LAXACLEAR), OLOPATADINE HYDROCHLORIDE (PATANASE), MONTELUKAST SODIUM (SINGULAIR), FLUTICASONE PROPIONATE (FLONASE [FLUTICASONE PROPIONATE]), FAMOTIDINE (PEPCID [FAMOTIDINE]), DESLORATADINE (CLARINEX [DESLORATADINE]), BIFIDOBACTERIUM INFANTIS (ALIGN), ALOE FEROX LATEX (CAPE ALOE), VITAMIN C [ASCORBIC ACID], BIOTIN (VITAMIN B7), BONE UP, COLECALCIFEROL (NOW VITAMIN D3), COLECALCIFEROL (CARLSON VITAMIN D3), AMYLASE, CELLULASE, LIPASE, MALTASE, PROTEASE NOS, SUCRASE, TILACTASE (DIGESTIVE ENZYMES [AMYLASE;CELLULASE;LIPASE;MALTASE;PROTEASE NOS;SUCRASE;TILACTASE]), DOCUSATE SODIUM, NATURE MADE ANTIOXIDANT FORMULA PLUS MINERALS, NIACINAMIDE and CALCIUM LEVOMEFOLATE (METHYL FOLATE [CALCIUM LEVOMEFOLATE]) for an unknown indication.   On 14-Aug-2021 at 2:00 PM, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 16-Jan-2022 at 12:15 PM, received fourth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced COVID-19 (Rebound case of COVID-19 after treatment with Paxlovid therapy was completed). The patient was treated with NIRMATRELVIR, RITONAVIR (PAXLOVID) from 21-May-2022 to 25-May-2022 for COVID-19 treatment, at an unspecified dose and frequency. At the time of the report, COVID-19 (Rebound case of COVID-19 after treatment with Paxlovid therapy was completed) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In May 2022, SARS-CoV-2 test: positive (Positive) Positive and negative (Negative) Negative (after paxlovid treatment). On 03-Jun-2022, SARS-CoV-2 test: positive (Positive) Positive (9 days after paxlovid treatment).         On 03-Jun-2022 at 09:30, the patient had rebound of COVID-19 after treatment with Paxlovid therapy was completed and was tested COVID-19 negative. The patient was tested positive for COVID-19 again 9 days after last Paxlovid dose.  Company Comment: This is a spontaneous case concerning a 60-year-old female patient with no relevant medical history, who experienced the unexpected, non-serious adverse event of special interest of COVID-19, approximately 4 months after receiving a dose of mRNA-1273 vaccine (fourth COVID-19 vaccine). The patient was treated with Nirmatrelvir/Ritonavir for 5 days and tested negative after treatment completion. 9 days after the treatment completion of Paxlovid, the patient tested positive. The outcome of the event was unknown at the time of the report. The benefit-risk relationship of mRNA-1273 is not affected by this report.; Sender's Comments: This is a spontaneous case concerning a 60-year-old female patient with no relevant medical history, who experienced the unexpected, non-serious adverse event of special interest of COVID-19, approximately 4 months after receiving a dose of mRNA-1273 vaccine (fourth COVID-19 vaccine). The patient was treated with Nirmatrelvir/Ritonavir for 5 days and tested negative after treatment completion. 9 days after the treatment completion of Paxlovid, the patient tested positive. The outcome of the event was unknown at the time of the report. The benefit-risk relationship of mRNA-1273 is not affected by this report.